arrow
D

Daniela S. Thommen

oncode institute
H指数:25
被引数:7,929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Guidelines for T cell nomenclature

T细胞命名指南

2025-11-180
OAAI
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

新辅助伊匹木单抗和纳武利尤单抗在可切除皮肤鳞状细胞癌中的应用:一项随机Ⅱ期临床试验

2025-10-080
OAAI
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
2024-04-244
OAAI
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma (Jul, 10.1038/s43018-023-00610-2, 2023)

白细胞介素17信号支持双重CTLA-4和PD-1检查点抑制在黑色素瘤中的临床益处 (7月,10.1038/s43018-023-00610-2,2023)

2023-08-140
OAAI
Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment

双重免疫检查点阻断可诱导功能失调的CD8 T细胞和激活的Treg区室发生类似的改变

2023-08-0711
OAAI
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

白细胞介素17信号支持黑色素瘤双重CTLA-4和PD-1检查点抑制的临床益处

2023-07-3117
OAAI
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
2023-02-0229
OAAI
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
2022-07-1922
OAAI
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
2022-07-1334
OA
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

一种离体肿瘤片段平台,用于剖析对癌症PD-1阻断的反应

2021-07-08194
PREAI